- Home
- Companies
- asia middle east
- cells i treefrog therapeutics
Refine by
Locations
- Asia & Middle East
- Afghanistan
- Armenia
- Azerbaijan
- Bahrain
- Bangladesh
- Bhutan
- Brunei Darussalam
- Cambodia
- China
- East Timor
- Georgia
- Guam
- India
- Indonesia
- Iran
- Iraq
- Israel
- Japan
- Jordan
- Kazakhstan
- Kuwait
- Kyrgyzstan
- Laos
- Lebanon
- Malaysia
- Maldives
- Mongolia
- Myanmar
- Nepal
- North Korea
- Oman
- Pakistan
- Palestinian Territories
- Philippines
- Qatar
- Russia
- Saudi Arabia
- Singapore
- South Korea
- Sri Lanka
- Syria
- Taiwan
- Tajikistan
- Thailand
- Turkmenistan
- United Arab Emirates
- Uzbekistan
- Vietnam
- Yemen
Cells I Treefrog Therapeutics Suppliers Near Asia Middle East
29 companies found
based inAtlanta, GEORGIA (US) (USA)
Transforming the manufacture of cell-based therapeutics into a large-scale, lower-cost, reproducible, and high-quality engineered process, for broad industry and clinical ...
Over 25 companies and 15 academic institutions collaborated together with government agencies to produce a national roadmap on cell therapy manufacturing. The National Cell Manufacturing Consortium (NCMC) is the first U.S. based national consortium ...
based inIndianapolis, INDIANA (USA)
Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed ...
Our Shielded Living Therapeutics platform combines advanced cell engineering with innovations in biocompatible materials, potentially enabling our products to produce a wide range of therapeutic molecules that may be missing or deficient in the ...
based inParis, FRANCE
We are a biotech company combining microfluidics, digitalization and bioengineering to make high quality biological therapies at affordable cost and minimized environmental impact. Therapeutic cells can multiply in the patient's body. This allows ...
based inCarlsbad, CALIFORNIA (USA)
Our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated ...
based inParis, FRANCE
Curadigm is an early-stage company focused on shifting the paradigm of therapeutic clearance, bioavailability, and efficacy to improve treatment outcomes for millions of patients. Curadigm was spun-off from Nanobiotix, a late-stage clinical company, ...
Curadigm’s technology was developed to address a critical challenge facing intravenously administered therapeutics: How can you efficiently deliver a drug to your tissue of interest without rapid clearance? To address this, we ...
based inSugar Land, TEXAS (USA)
Our mission is to develop and deliver adult stem cell solutions that are safe, effective and affordable for incurable conditions. Our vision is a world where stem cells are regularly used to not only treat disease but prevent it. Today, medicine is ...
based inHaifa, ISRAEL
Pluristem Therapeutics Inc. is a clinical-stage regenerative medicine company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, muscle injuries, ...
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. PLX-R18 is ...
based inAustin, TEXAS (USA)
Direct Biologics is a leader in regenerative medicine, focusing on the development of next-generation bioactive products derived from stem cells. Their innovative technology centers on Extracellular Vesicle (EV) products, which are formulated from ...
based inSan Diego, CALIFORNIA (USA)
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary ...
based inMilpitas, CALIFORNIA (USA)
ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT and other gene editing technologies developed after 12 ...
based inSalt Lake City, UTAH (USA)
DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics’ cell isolation ...
DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we believe will be a profound therapeutic option for millions of patients suffering from the debilitating effects of low back ...
based inCottesloe, AUSTRALIA
Neuroscientific Biopharmaceuticals is an Australian public company (ASX:NSB) developing novel peptide-based pharmaceutical products that target a number of neurological disorders and diseases of the eye that have high unmet medical need. Our vision ...
Multiple indications with unmet medical need. “Our company goal is to create new products that reach their target in the brain and act as a protector against nerve cells injury. Currently, there are no approved drugs that can slow down or halt ...
based inFreiburg, GERMANY
Sartorius CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. We develop, manufacture and market human cytokines, growth factors, and other ...
based inHouston, TEXAS (USA)
cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT). The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Therapeutic Mitochondria ...
based inSunnyvale, CALIFORNIA (USA)
We are developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Our Mission: To improve the lives of patients with cardiovascular and pulmonary diseases through the development of ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
based inCambridge, MASSACHUSETTS (USA)
At BlueRock, our mission is to create authentic cellular medicines to reverse devastating diseases, with the vision of improving the human condition. Until recently, scientists believed that mature adult cells were permanently locked into their ...
With our cell+gene platform, BlueRock is aiming to redefine the very way we treat disease, moving from addressing mere symptoms to restoring health lost to cell damage or degeneration. Instead of prescribing a pill to treat tremors in patients with ...
based inSan Francisco, CALIFORNIA (USA)
Vetherapy is a team of scientists, bioengineers, veterinarians and entrepreneurs on a mission to bring stem cell therapies to treat complex and challenging diseases for pet. Vetherapy stem cell therapies are the result of nearly 2 decades of ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. A broader window of opportunity. Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety ...
based inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
